Niagara Falls, NY, Nov. 24, 2023 (GLOBE NEWSWIRE) — Positron Corporation (Positron or the Company) (OTC: POSC) has announced the sale of its innovative Attrius® PET System to a prominent cardiovascular practice in Pennsylvania. The practice will benefit from the high-resolution images and accurate measurements of absolute blood flow provided by the Attrius PET scanner.
Positron is the sole provider of a dedicated PET scanner optimized for nuclear cardiology in the industry. The Attrius PET System is a 2D quantitative PET scanner that complements coronary flow reserve software, enabling precise assessments of blood flow.
Through Positron’s Lease to Own & Services Program, the new customer will receive a complete package of the Attrius PET System and Clinical & Technical Services for a five-year term. This program offers nuclear imaging practices seeking the PET modality a viable operational model without any upfront capital expenses. Positron expects to enter more lease to own/services agreements with other interested parties as they complete site preparation and radiopharmaceutical supply agreements.
Adel Abdullah, President of Positron, expressed his delight in assisting customers’ transition from SPECT to cardiac PET imaging. The Attrius PET is a powerful tool for advanced cardiac studies and diagnostics, and Positron’s physicians and practices will benefit from the innovative lease to own program. Abdullah emphasized the company’s commitment to providing the best quality medical care through advanced PET technology, clinical services, and competitive pricing. Positron’s clinical team will offer expert training and assistance to ensure customers fully utilize the benefits of the Attrius PET system and quantification software.
Positron Corporation specializes in providing state-of-the-art PET imaging systems and clinical services to nuclear medicine healthcare providers across North America. With its dedicated PET system, Attrius PET, and unique market position, Positron leads the way in the adoption of cardiac PET, contributing to the growth of the nuclear imaging market.
In the near future, Positron plans to introduce a state-of-the-art PET-CT molecular imaging device that enables nuclear cardiologists to fully leverage the capabilities of molecular imaging and nuclear medicine. This development will also allow Positron to cater to the extensive demands of the oncology diagnostics market. The company will continue advancing its technology through its manufacturing and research venture with Neusoft Medical Systems’s subsidiary, Shenyang Intelligent Neuclear Medical Technology Co. Ltd.
The announcement from Positron Corporation regarding the sale of their Attrius PET System to a prominent Pennsylvania-based cardiovascular practice demonstrates the growing interest and adoption of the PET modality, particularly in the field of nuclear cardiology. With advanced imaging capabilities, accurate measurements, and a lease to own/services program that eliminates upfront capital expenses, the Attrius PET System provides nuclear imaging practices with high technology and cost-effective solutions. Positron Corporation’s commitment to meeting the needs of its customers and providing exceptional quality medical care further solidifies the company’s position as a leader in the industry.
For additional information, please visit Positron Corporation’s website at www.positron.com or contact: investor@positron.com.
